LEE011
Breakthrough therapy designation for Novartis in advanced breast cancer treatment
August 3, 2016Research and Development, Sales and Marketing Breakthrough Therapy Designation, FDA, LEE011, Novartis, ribociclib
Novartis has announced that the US Food and Drug Administration (FDA) has granted a breakthrough therapy designation to LEE011 (ribociclib) …
Breast cancer trial stopped after meeting primary endpoint early
May 18, 2016Research and Development LEE011, Novartis, breast cancer, progression free survival, ribociclib
A Phase III trial evaluating LEE011 (ribociclib), developed by Novartis, has been stopped early after a recommendation from an independent …
Pfizer breast cancer pill gets FDA nod
October 14, 2014Research and Development, Sales and Marketing FDA, Femera, LEE011, Pfizer, bemaciclib, breast cancer, palbociclib
Pfizer’s experimental breast cancer drug palbociclib has been accepted and granted a priority review by the US Food and Drug …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
August 14, 2026
